How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Bovine Babesiosis Vaccines Market
- By Vaccine Type: Live Attenuated Vaccines, Killed/Inactivated Vaccines, Recombinant/Subunit Vaccines, DNA Vaccines
- By Target Species: Cattle, Buffalo, Other Bovine Species
- By Application: Preventive Vaccination, Therapeutic Vaccination
- By End User: Veterinary Hospitals and Clinics, Livestock Farms, Research and Academic Institutes
- By Distribution Channel: Veterinary Distributors, Online Veterinary Pharmacies, Direct Sales
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Live Attenuated Vaccines leads By Vaccine Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.170 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Bovine Babesiosis Vaccines Market report
A complete, evidence-based study - 12 chapters and 113 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Vaccine Type 4
Target Species 3
Application 2
End User 3
Distribution Channel 3
Companies profiled
Boehringer Ingelheim
Zoetis
Bayer Animal Health
Elanco Animal Health
Ceva Santé Animale
Virbac
Merial (now part of Boehringer Ingelheim)
Indian Immunologicals Ltd.
Vaccine manufacturers in China such as Lanzhou Institute of Biological Products
Janssen Animal Health (Johnson & Johnson)
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Boehringer Ingelheim
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Zoetis
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Bayer Animal Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Elanco Animal Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Ceva Santé Animale
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Virbac
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Merial (now part of Boehringer Ingelheim)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Indian Immunologicals Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Vaccine manufacturers in China such as Lanzhou Institute of Biological Products
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Janssen Animal Health (Johnson & Johnson)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$11,947M by 2033 · 10.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Live Attenuated Vaccines43.6
- Killed/Inactivated Vaccines22.9
- Recombinant/Subunit Vaccines14.2
- DNA Vaccines19.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,790M → $4,387M · 11.9%
Europe$1,247M → $2,504M · 9.1%
Asia Pacific$1,139M → $2,498M · 10.3%
Latin America$705.0M → $1,722M · 11.8%
Middle East and Africa$542.3M → $1,217M · 10.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.332026
10.342027
10.362028
10.362029
10.382030
10.382031
10.402032
10.422033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Boehringer Ingelheim22.8
- Zoetis16.3
- Bayer Animal Health6.3
- Elanco Animal Health6.6
- Ceva Santé Animale8.8
- Virbac11.1
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Vaccine Type22.3%
Target Species8.9%
Application27.4%
End User16.6%
Distribution Channel24.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.6
- Europe20.3
- Asia Pacific20.3
- Latin America14.0
- Middle East and Africa9.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | 85 | 79 | 85 | 88 | 88 | 84 | 85 |
| Zoetis | 69 | 93 | 79 | 79 | 90 | 90 | 83 |
| Bayer Animal Health | 78 | 84 | 79 | 78 | 65 | 63 | 75 |
| Elanco Animal Health | 58 | 58 | 68 | 62 | 64 | 62 | 62 |
| Ceva Santé Animale | 67 | 73 | 68 | 69 | 64 | 51 | 65 |
| Virbac | 58 | 58 | 52 | 64 | 68 | 62 | 60 |
| Merial (now part of Boehringer Ingelheim) | 64 | 57 | 42 | 63 | 62 | 53 | 57 |
| Indian Immunologicals Ltd. | 48 | 47 | 43 | 43 | 51 | 53 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Boehringer Ingelheim
- Zoetis
- Bayer Animal Health
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim | ✓ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Zoetis | ◐ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Bayer Animal Health | ✓ | ◐ | ✓ | ✓ | ◐ | − |
| Elanco Animal Health | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Ceva Santé Animale | ◐ | ✓ | ✓ | ◐ | − | − |
| Virbac | − | − | − | ◐ | ◐ | − |
| Merial (now part of Boehringer Ingelheim) | ✓ | − | − | − | ◐ | ◐ |
| Indian Immunologicals Ltd. | − | ◐ | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Boehringer Ingelheim85
2Zoetis83
3Bayer Animal Health75
4Ceva Santé Animale65
5Elanco Animal Health62
6Virbac60
7Merial (now part of Boehringer Ingelheim)57
8Indian Immunologicals Ltd.48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Boehringer IngelheimZoetis
Challenger1
Strong scale, closing on the leaders.
Bayer Animal Health
Contender4
Focused players with pockets of strength.
Elanco Animal HealthCeva Santé AnimaleVirbacMerial (now part of Boehringer Ingelheim)
Niche1
Specialists in a single segment or region.
Indian Immunologicals Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Vaccine Type in North America, then scale across Bovine Babesiosis Vaccines Market — a $218M beachhead inside a $3.33B market.
Beachhead (SOM)$218Mobtainable near-term
Serviceable (SAM)$1.36Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Live Attenuated Vaccines
Best fit — highest urgency & budget in Vaccine Type.
Economic buyer79 fit
Killed/Inactivated Vaccines
Strong fit — clear ROI and a fast path to value.
End user64 fit
Recombinant/Subunit Vaccines
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vaccine Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Target Species & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve19%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Vaccine Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Bovine Babesiosis Vaccines Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified21%
Evaluation15%
Closed-won7%
$16.8KCAC
$77KLTV
4.6:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Bovine Babesiosis Vaccines Market is a high-growth opportunity — $7.17B by 2033, compounding at 10.9%.
TAM · 2025$3.14Btoday
TAM · 2033$7.17Bforecast
CAGR10.9%2027–2033
Cumulative$44.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.17BTotal addressable market
SAM$2.96BServiceable available market
SOM$636MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.9% CAGR
Demand compounds through 2033, outpacing GDP across Vaccine Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vaccine Type moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.17BLarge & growingTAM by 2033 at 10.9% CAGR
$2.96BServiceable nowreachable with today’s model
$636MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.59BBear7.1% CAGR
$7.17BBase10.9% CAGR
$9.18BBull14.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Target Species optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Bovine Babesiosis Vaccines Market — a $4.69B market by 2033. Plan: grow share from 10.8% to 17.2%.
Market size · 2033$4.69Btotal addressable
Market CAGR8.2%2027–2033
Target share17.2%from 10.8% today
Revenue ambition$806Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.8% | 17.2% | At risk |
| Revenue | $553M | $806M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 31.5% | 42.0% | On track |
| Customer retention | 91.8% | 94.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vaccine Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Target Species capability
A defensible second engine — invest in Target Species to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vaccine Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Target Species
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $86M capacity & capability investment
- Greenlight bolt-on M&A in Target Species
- Authorise North America expansion plan
- Fund R&D program for Vaccine Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Bovine Babesiosis Vaccines Market conversation — a $8.46B market you can size, segment and defend in minutes.
Market size · 2033$8.46Btotal opportunity
Growth11.5%CAGR to 2033
Addressable buyers1,367+accounts in scope
Typical ROI7.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vaccine Type
Goal Grow share in Vaccine Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.5×return on cost, year one
< 2 mopayback period
$56K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Boehringer IngelheimZoetisBayer Animal HealthElanco Animal HealthCeva Santé AnimaleVirbacMerial (now part of Boehringer Ingelheim)Indian Immunologicals Ltd.+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Bovine Babesiosis Vaccines Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Bovine Babesiosis Vaccines Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Bovine Chymotrypsin Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportBovine Insulin Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportBovine Lactoferrin Manufacturers Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportBovine Pancreas Trypsin Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportBovine Pericardial Tissue Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportBovine Pericardium Membrane Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportBovine Respiratory Disease Treatment Drugs Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportBovine Respiratory Diseases Treatment Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportBovine-based Collagen Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportBow Tie Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportBowed Roll Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportBowel Management System Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.